SPRC
SciSparc Ltd. (NASDAQ)
Healthcare — Biotechnology
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Price History
Fundamentals
| Market Cap | $2.95M |
| P/E Ratio (TTM) | 0.05 |
| Forward P/E | - |
| EPS (TTM) | $98.07 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | -34.50% |
| ROE | -178.39% |
| Debt/Equity | 7.11 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 17.0 |
| Beta | 2.43 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $80.10 |
| 52-Week Low | $2.98 |
| 50-Day Avg | $7.13 |
| 200-Day Avg | $14.47 |
| Avg Volume | $1.11M |
| Volume | 335 |
Performance Analysis
NEUTRALSPRC presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:32 UTC
Back to Screener Export Report